Compositions and methods comprising magnetic resonance contrast agents
The present invention relates to compositions and methods for imaging with magnetic resonance contrast agents. In particular, the present invention provides targeted contrast agents for selective imaging.
1. A composition comprising an MRI contrast agent, wherein said MRI contrast agent comprises:
a) a ligand moiety, wherein said ligand moiety comprises progesterone,
b) a contrast moiety comprising M-DO3A, wherein the structure of said M-DO3A is as follows:
wherein M is a paramagnetic metal ion selected from the group consisting of: Gd(III), Fe(III), Mn(II), Y(III), Cr(III), Eu(III), and Dy(III), and
c) a linkage region, wherein said linkage region comprises a triazole ring, wherein said linkage region covalently links said ligand moiety to said contrast moiety, and wherein said linkage region is directly attached to said ligand moiety and said contrast moiety, and
wherein said MRI contrast agent is water soluble.
2. The composition of claim 1 , wherein said paramagnetic metal ion is selected from the group comprising Gd(III) and Eu(III).
3. The composition of claim 1 , wherein said paramagnetic metal ion comprises Gd(III).
4. The composition of claim 1 , wherein said linker region further comprises one or more methylene carbons.
5. The composition of claim 4 , wherein said linker region comprises 3 or 6 methylene carbons.
6. A method comprising:
a) administering a composition of claim 1 to a cell or tissue; and
b) producing a magnetic resonance image of said cell or tissue.
7. The method of claim 6 , wherein said cell or tissue expresses progesterone receptor.
8. The method of claim 7 , wherein said progesterone binds to said progesterone receptor.
9. The method of claim 8 , wherein binding of said progesterone to said progesterone receptor results in localization of said composition.
10. The method of claim 6 , wherein said cell or tissue does not express progesterone receptor.